Inhibitor for the proliferation of human lung cancer A549 cells
JP2026168570APending Publication Date: 2026-10-16WATANABE OYSTER LAB
1 Cites 0 Cited by
Patent Information
- Application Number
- JP2025061751
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-04-03
- Publication Date
- 2026-10-16
AI Technical Summary
Benefits of technology
【0012】 本発明によれば、DHMBAがin vitroでヒト肺腺がんNSCLC A549細胞に対しての抗がん作用を有するかどうかが確認でき、DHMBAによる培養が、EGFシグナル伝達に関連する様々な経路を抑制することでA549細胞の増殖を抑制し、A549細胞の死滅を刺激することで、がん細胞の増殖の進展を阻害することが確認でき、さらに、DHMBAによる培養が、活性酸素産生を抑制し、がん細胞の接着や遊走を含む転移活性を阻害することが確認でき、もって、DHMBAがin vitroでヒト肺腺がん細胞に対して抗がん作用を有することが見出せ、肺がん治療の新たな戦略が提供出来るとの優れた効果を奏するものである。
✦ Generated by Eureka AI based on patent content.
Abstract
This invention confirms whether DHMBA has an anticancer effect on human lung adenocarcinoma (NSCLC) A549 cells in vitro. It confirms that culturing with DHMBA inhibits the proliferation of A549 cells by suppressing various pathways related to EGF signaling, stimulating and promoting the death of A549 cells, and thereby inhibiting the progression of cancer cell proliferation. Furthermore, it confirms that culturing with DHMBA suppresses reactive oxygen species production and inhibits metastatic activity, including adhesion and migration of cancer cells. Thus, this invention finds that DHMBA has an anticancer effect on human lung adenocarcinoma cells in vitro, providing a new strategy for lung cancer treatment. [Solution] The present invention features 3,5-dihydroxy-4-methoxybenzyl alcohol as an active ingredient and has an inhibitory effect on the proliferation of human lung cancer A549 cells.
Need to check novelty before this filing date? Find Prior Art